{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/fr\/","title":"Les patients qui ne r\u00e9agissent pas favorablement aux TNFi ont besoin d\u2019un plus grand choix d\u2019agents biologiques - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"YsKXGOW7QF\"><a href=\"https:\/\/themedicalxchange.com\/fr\/2015\/11\/19\/congres-de-2015-de-lamerican-college-of-rheumatolo\/\">Les patients qui ne r\u00e9agissent pas favorablement aux TNFi ont besoin d\u2019un plus grand choix d\u2019agents biologiques<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/fr\/2015\/11\/19\/congres-de-2015-de-lamerican-college-of-rheumatolo\/embed\/#?secret=YsKXGOW7QF\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Les patients qui ne r\u00e9agissent pas favorablement aux TNFi ont besoin d\u2019un plus grand choix d\u2019agents biologiques\u00a0\u00bb &#8212; The Medical Xchange\" data-secret=\"YsKXGOW7QF\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2015\/11\/2355_ACR_2015_fr_Fig_1.JPG","thumbnail_width":960,"thumbnail_height":720,"description":"San Francisco \u2013 Si les inhibiteurs du facteur de n\u00e9crose tumorale (TNF) \u2014 et les autres agents biologiques qui ont suivi \u2014 ont \u00e9t\u00e9 pour beaucoup dans la ma\u00eetrise de la polyarthrite rhumato\u00efde (PR) mod\u00e9r\u00e9e ou grave, il n\u2019en demeure pas moins que les patients dont le traitement cibl\u00e9 initial \u00e9choue ont besoin de nouveaux produits. Or des donn\u00e9es pr\u00e9sent\u00e9es lors du congr\u00e8s de 2015 de l\u2019ACR confirment que des nouveaux agents biologiques permettent aux patients atteints de PR dont la maladie \u00e9volue malgr\u00e9 un traitement cibl\u00e9 initial de renouer avec des effets th\u00e9rapeutiques positifs."}